“While several bigger groups are being rewarded for Covid-19 and other clinical successes, earlier-stage and higher-risk biotechs are, for now, out of favour."
— Evaluate Vantage, Vantage 2022 Preview Report

"(Vaccine stocks are) in the news every single day and people who aren’t biotech experts tend to invest in what they hear. They’re hearing about Moderna or Pfizer and BioNTech and are throwing money at them."
— Brad Loncar, Loncar Investments

Who We Are

The Investing News Network is a growing network of authoritative publications delivering independent, unbiased news and education for investors. We deliver knowledgeable, carefully curated coverage of a variety of markets including gold, cannabis, biotech and many others. This means you read nothing but the best from the entire world of investing advice, and never have to waste your valuable time doing hours, days or weeks of research yourself.

At the same time, not a single word of the content we choose for you is paid for by any company or investment advisor: We choose our content based solely on its informational and educational value to you, the investor.

So if you are looking for a way to diversify your portfolio amidst political and financial instability, this is the place to start. Right now.